Durvalumab Added to Standard of Care Improves Survival Outcomes for Patients With Muscle-Invasive Urothelial Carcinoma
According the phase 2 SAKK 06/17 trial, adding durvalumab to the standard of care regimen for patients with resectable, muscle-invasive urothelial carcinoma improved event-free survival (EFS) and overall survival (OS).
This multicenter, international, investigator-initiated, open-label phase 2 trial enrolled 57 patients with urothelial carcinoma evaluable for full analysis. Patients received neoadjuvant chemotherapy, 4 cycles of gemcitabine-cisplatin plus 1500 mg durvalumab every 3 weeks for 4 doses. Within 4 to 8 weeks following chemoimmunotherapy, radical cystectomy with lymph node dissection or nephroureterectomy with lymph node dissection was performed. Adjuvant durvalumab began 4 to 12 weeks after surgery, at 1500 mg once every 4 weeks for a total of 10 cycles. The primary end point of this study was EFS at 2 years. Secondary end points included EFS, OS, recurrence-free survival following R0 resection, and adverse events.
With a median follow-up duration of 40 months, the EFS at 2 years was 75.7%, with a median EFS not yet reached. The 3-year EFS was 73.4%. The OS at 2 years was 85.0%, and 80.8% at 3 years. Of the 52 patients who underwent surgery, 51 had an R0 resection, and 1 had R1. Of all patients who underwent surgery, 17 patients (33%) had a complete pathologic response and 31 (60%) had a pathologic response <upT2 ypN0. Among the 51 patients with an R0 resection, there was an RFS of 83.4% at 2 years post-surgery and of 80.9% at 3 years.
Of all patients, 42% experienced a grade 3 treatment-related adverse event and 11% experienced a grade 3 treatment-related adverse event related to adjuvant durvalumab. There were 25% who experienced a grade 4 treatment-related adverse event and 4% related to adjuvant durvalumab.
Study authors concluded, “The addition of perioperative durvalumab to the standard of care for patients with resectable [muscle-invasive urothelial carcinoma] results in high EFS and OS at 2 years.”
Associate editor of Journal of Clinical Oncology, Michael Anthony Carducci, MD, Johns Hopkins Medicine, Baltimore, Maryland, added, “This study is unique in exploring a time to event endpoint in the perioperative setting, rather than pathologic complete response. Phase [3] trials are ongoing which should inform us on options for localized muscle invasive bladder cancer.”
Source:
Cathomas R, Rothschild SI, Hayoz S, et al. Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phase II trial SAKK 06/17. Published online August 17, 2023. doi: 10.1200/JCO.23.00363


